The aim of this project is to develop innovative drug products, which are able to control the resulting drug distribution in the patient’s body: The drug amount at the site of action is to be optimized, and the amount that is “lost” into the rest of the human body is to be minimized. This is to be achieved by “site-specific delivery systems”, which release the drug at a controlled rate at the site of action. Thus, the therapeutic efficacy will be improved & undesired side effects reduced. This will help reducing the current cost burden on our healthcare systems due to adverse drug effects. Specifically, the project aims at developing innovative site-specific drug delivery systems for the colon, inner ear, peritoneal cavity and breast.
(1) Novel drug products for a safer and more efficient treatment of patients suffering from:
- a) Crohn’s disease and ulcerative colitis
- b) Ovarian cancer with metastases in the peritoneal cavity
- c) Breast resection due to cancer
- d) Hearing loss/deafness.
(2) A novel in vitro characterization method facilitating the development of “colon targeting systems” and assuring adequate quality control during production.
(3) A feasibility study, demonstrating the performance of the newly developed drug delivery systems.
University of Lille (Lead partner, Prof. Siepmann), University of Cambridge (Prof. Zeitler), Ghent University (Prof. Vervaet), University College London (Prof. Basit), Leiden University (Prof. Jiskoot), Delft University of Technology (Prof. Zadpoor), Lille University Hospital (Mrs. Leal), Lattice Medical (Dr. Payen), Prodigest (Dr. Marzorati) and the Technological Transfer Office North of France (M. Beitone).
Addenbrooke’s Hospital, Dr. Reddy’s Research & Development B.V., Eurasanté, FabRx, Intract Pharma, Medtronic, Oticon Medical, Pfizer, the Queen Elizabeth The Queen Mother Hospital, and Vesale Pharma.
This project is funded by the Interreg 2 Seas programme 2014-2020 and the European Regional Development Fund under subsidy contract “Site Drug 2S07-033”.
Project budget: 4 885 145 €; ERDF amount: 2 931 087 €; ERDF rate: 60%
Start Date: 01/01/2020; End Date: 30/09/2022